TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01268943
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study: NCT01268943
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study: NCT00506415
Drug: Placebo to 15 cm^2 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of rivastigmine transdermal patch 15 cm\^2.
Study: NCT00506415
Drug: Placebo to 10 cm^2 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of rivastigmine transdermal patch 10 cm\^2.
Study: NCT01954056
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: • 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
Study: NCT01954056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
Study: NCT03328507
Drug: BLI4900
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI4900 Bowel Preparation
Study: NCT03328507
Drug: PEG Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-based bowel preparation
Study: NCT01742130
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03451890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT00392340
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01703260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast placebo-matching dose
Study: NCT00053196
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants
Study: NCT01268943
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study: NCT03422068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation
Study: NCT02927951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg bid
Study: NCT04122586
Drug: Tongxieyaofang(granule)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
Study: NCT00351195
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00116818
Drug: GW685698X aqueous nasal spray
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03742518
Drug: Topical SM04554 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication application will be performed by the individual subject at approximately the same time each day.
Study: NCT02215200
Drug: Placebo (for ATG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered by IV infusion to mimic ATG
Study: NCT02215200
Drug: Placebo (for GCSF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo prepared to mimic 6mg subcutaneous injection of GCSF
Study: NCT01438892
Drug: tDMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional DMARDs for RA
Study: NCT01438892
Drug: biodmards
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic DMARDs
Study: NCT03032510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03437213
Drug: Total intravenous anesthesia group
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
Study: NCT03404518
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen as first line therapy every 6 hours as needed for pain control
Study: NCT01291849
Drug: Dixon up-and-down method
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
Study: NCT01052181
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sachets monthly for an year
Study: NCT04018612
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is an analgesic and antipyretic
Study: NCT00639496
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02462772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
Study: NCT00558467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01087216
Drug: Bras B : The group control
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
Study: NCT00002596
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02176655
Drug: VVD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Study: NCT02176655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Study: NCT01155180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02969200
Drug: Enzyme replacement therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
Study: NCT03693183
Drug: Ketorolac/HPMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
Study: NCT00002875
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00556946
Drug: Combined Photodynamic & Pulsed Dye Laser Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
Study: NCT00396656
Drug: Hydrochlorothiazide (HCTZ))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 or 25 mg tablets orally once a day (od) in the morning.
Study: NCT00765336
Drug: minocycline extended release
Normalized name: minocycline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg extended release minocycline HCL, once daily for 84 days.
Study: NCT00656825
Drug: P144 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: P144 cream will be given at a dose of 100 μg/mL
Study: NCT00656825
Drug: P144 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: P144 cream will be given at a dose of 200 μg/mL
Study: NCT00656825
Drug: P144 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: P144 cream will be given at a dose of 300 μg/mL
Study: NCT00656825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be randomly given to 4 subjects in each panel
Study: NCT01358929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to RO6807952
Study: NCT01358929
Drug: RO6807952
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating subcutaneous dose
Study: NCT02972905
Drug: GSK2269557 ELLIPTA DPI
Normalized name: ECLIPTA PROSTRATA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
Study: NCT02972905
Drug: Placebo ELLIPTA DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ELLIPTA DPI contains lactose
Study: NCT01235546
Drug: Azithromycin and standard of care
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
Study: NCT03299660
Drug: Capecitabine Pill
Normalized name: capecitabine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
Study: NCT04031846
Drug: Rotarix™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
Study: NCT04031846
Drug: Infanrix™ hexa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
Study: NCT04031846
Drug: V114
Normalized name: Pneumococcal 15-valent Conjugate Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
Study: NCT04031846
Drug: Prevenar 13™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
Study: NCT01235546
Drug: Placebo and standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 cc normal saline, plus standard of care (cephazolin or clindamycin)
Study: NCT00550043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04201574
Drug: ALY688 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALY688 0.1% Ophthalmic Solution
Study: NCT04201574
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT01095562
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 Dose 1, ABT-126 Dose 2
Study: NCT01095562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04273529
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg，po，qn，for 14 days.
Study: NCT03335488
Drug: NaPBA
Normalized name: Caffeine 200 MG Oral Powder for Suspension [SNAPBACK STIMULANT POWDERS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: * NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose
Study: NCT01016951
Drug: AZD9164 Turbuhaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg.
Study: NCT01016951
Drug: Placebo Turbuhaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation via Turbuhaler, MAD
Study: NCT03349060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT02565628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01977755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03557619
Drug: ethinyl estradiol/levonorgestrel
Normalized name: ETHINYL ESTRADIOL/LEVONORGESTREL
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet; oral
Study: NCT03222622
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically twice daily for 12 consecutive weeks
Study: NCT02954601
Drug: ORMD-0801 (bid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 = ORMD-0801 (bid)
Study: NCT02954601
Drug: ORMD-0801 (tid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3 = ORMD-0801 (tid)
Study: NCT01269216
Drug: 5-FU with leucovorin
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
Study: NCT00760916
Drug: UT-15C 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: UT-15C 1 mg
Study: NCT00760916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02236962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00318474
Drug: MMF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo only, oral administration
Study: NCT00318474
Drug: ACEi
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer same as pre-treatment regimen.
Study: NCT00318474
Drug: FOS
Normalized name: Fostex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer same as pre-treatment regimen
Study: NCT00002772
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002772
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00204919
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-monthly placebo capsules
Study: NCT03833297
Drug: Drugs inducing hepatological toxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce hepatological toxicities
Study: NCT00277238
Drug: CPG10101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Study: NCT00277238
Drug: CPG10101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Study: NCT02333344
Drug: Zoledronic acid 5mg
Normalized name: ZOLEDRONIC ACID 5MG/BTL INJ,100ML
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: two-year Zoledronic acid 5mg infusion treatment
Study: NCT03040778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT01543178
Drug: double-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day (double-blind)
Study: NCT02182492
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 250 mg tablet once daily for 3 months
Study: NCT02182492
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate nasal spray 200 μg/d for 3 months
Study: NCT00885196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00885196
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04630002
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be available as oral tablets.
Study: NCT04644432
Drug: Medication (A specification is listed under each arm)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drugs and dosages are listed in the description of arms.
Study: NCT01821235
Drug: Neurontin® (gabapentin) batch B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
Study: NCT01821235
Drug: Gabasandoz® (gabapentin) batch B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
Study: NCT02988401
Drug: Placebo (Sterile diluent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
Study: NCT01394354
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
Study: NCT04354987
Drug: CKD-391 10/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)
Study: NCT04354987
Drug: D090, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: D090 and D337 co-administration(Other Name: Reference drug)
Study: NCT00264667
Drug: GW677954
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01767766
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGR-1202 Daily Oral Dose
Study: NCT02074358
Drug: Beriplex P/N (4-Factor PCC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02074358
Drug: Placebo (Saline solution)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03309943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one dose of Placebo on two separate occasions.
Study: NCT00023855
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02019264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT04303806
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: receive rosuvastatin orally once daily.
Study: NCT02027454
Drug: GSK1265744
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
Study: NCT02027454
Drug: GSK1265744 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
Study: NCT00628212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02025725
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray formulation with vehicle only
Study: NCT00122837
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02416609
Drug: Gem-based doublets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of Gem-based doublets
Study: NCT00546377
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02593097
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo twice daily
Study: NCT05215977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU
Study: NCT00665431
Drug: PN 400 (VIMOVO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen/20 mg esomeprazole bid
Study: NCT00665431
Drug: Rescue Antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid Tablets
Study: NCT01934582
Drug: UT-15C SR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01934582
Drug: treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label study drug.
Study: NCT02151305
Drug: Propofol, remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01487395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
Study: NCT01397877
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os, 60mg/j, until progression or unacceptable toxicity
Study: NCT01394731
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01063192
Drug: Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
Study: NCT00204776
Drug: Capecitabine and Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04104503
Drug: [14C]-Lu AF11167
Approvals — FDA: no, EMA: no, PMDA: no
Description: single iv microdose administered as a 15 minutes infusion
Study: NCT04104503
Drug: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT00404391
Drug: Hydrocodone/Acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet every 12 hours
Study: NCT00404391
Drug: Hydrocodone/Acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets every 12 hours
Study: NCT00404391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets every 12 hours
Study: NCT01031680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg single oral dose